SCHEMBL29437979

SCHEMBL29437979

CC(C)(C)c1cc(C#N)ccc1Oc1ccc(N)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.47
POLB P06746 2/20 0.47
RAB9A P51151 1/20 0.47
KEAP1 Q14145 1/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
ALDH1A1 P00352 2/20 0.40
BRCA1 P38398 1/20 0.40
HBB P68871 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ALOX5AP P20292 4/20 0.38
FEN1 P39748 4/20 0.38
KDM1A O60341 1/20 0.34
SCN9A Q15858 1/20 0.34
NR3C1 P04150 1/20 0.33
USP2 O75604 1/20 0.33
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
PDE4B Q07343 1/20 0.32
AR P10275 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12594102 1.00 KDM4E (0.47) KDM4EPOLBRAB9AKEAP1MEN1
SCHEMBL1979840 0.87 MEN1 (0.45) KDM4EPOLBRAB9AKEAP1MEN1
SCHEMBL23952714 0.86 AR (0.41) ALDH1A1ALOX5APFEN1NR3C1AR
SCHEMBL13720847 0.85 KDM1A (0.36) KDM4EPOLBRAB9AALDH1A1KDM1A
SCHEMBL12594180 0.83 KEAP1 (0.52) KDM4EPOLBRAB9AKEAP1MEN1
SCHEMBL13832478 0.81 NR3C1 (0.36) ALOX5APFEN1SCN9ANR3C1CYP2C19
SCHEMBL15302990 0.80 ALPL (0.36) KDM4EALOX5APFEN1SCN9ANR3C1
SCHEMBL9924313 0.80 HSPB1 (0.51) KDM4EPOLBMEN1KMT2AALDH1A1
SCHEMBL29437961 0.80 HSPB1 (0.51) KDM4EPOLBMEN1KMT2AALDH1A1
SCHEMBL21610183 0.79 NUDT1 (0.43) ALOX5APFEN1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 KDM4E 1460/4885POLB 4418/4885RAB9A 1403/4885
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 KDM4E 1460/4885POLB 4418/4885RAB9A 1403/4885
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS KCNN3, KCNA4, KCNA3 KDM4E 200/4885POLB 3774/4885RAB9A 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.